Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07755137

Feasibility, Acceptability, and Preliminary Effectiveness of Cognitive Behavioral Therapy for Depression in Autistic Youth in Clinical Settings

The goal of this clinical trial is to learn if Cognitive Behavioral Therapy for Depression in Autistic Youth (CBT-DAY) can improve depressive symptoms and related mechanisms in autistic youth aged 11-17 years with depression receiving care in outpatient clinical settings.

The main questions it aims to answer are:

* Does CBT-DAY lead to greater reductions in depressive symptom severity compared to treatment-as-usual (TAU)? * Does CBT-DAY improve key mechanisms (emotional reactivity, self-esteem, and autism self-knowledge) associated with depression outcomes?

Researchers will compare CBT-DAY versus treatment-as-usual (TAU) to see if CBT-DAY results in greater improvements in depressive symptoms and related outcomes.

Participants will:

* Complete baseline, mid-treatment, post-treatment, and 3-month follow-up assessments (surveys and interviews) * Be randomly assigned to receive either 12 weeks of CBT-DAY or treatment-as-usual * Participate in therapy sessions during the 12-week intervention period * Complete follow-up assessments three months after treatment to evaluate longer-term outcomes

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

11 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States

Location contact

Jessica Schwartzman, PhD

CONTACT

[email protected]

323-207-5910

Jessica Schwartzman, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Autistic youth:

  • Age 11 to 17 years
  • Prior clinical diagnosis of autism (per record review)
  • At least a fifth grade reading level
  • An ability to engage in sessions verbally (i.e., full length sentences)
  • Elevated symptoms of depression at baseline (RCADS)
  • Depression is a current clinical concern and participant is appropriate for intervention (per investigator determination)
  • At least one parent/caregiver willing and able to participate
  • Eligible to receive services at CHLA
  • If taking psychotropic medication, regimen must be stable for at least 8 weeks prior to baseline

Parents/Caregivers:

  • Age 18 years or older
  • Parent or legal guardian of participating youth
  • Able to provide informed consent
  • Comfortable reading, writing, or speaking English or Spanish
  • Willing to participate in study procedures

Exclusion criteria

Autistic youth:

  • Lifetime diagnosis of bipolar disorder, psychotic disorder, or intellectual disability
  • Severe suicidal or homicidal ideation or self-injury requiring immediate higher-level care
  • Currently receiving psychotherapy for depression
  • Changes in psychotropic medication regimen during study participation (participants may be withdrawn)
  • A reading level below fifth-grade
  • An inability to engage in sessions verbally (i.e., nonverbal, minimally verbal)

Parents/Caregivers:

  • Not the parent or legal guardian of the participating youth
  • Unable to provide informed consent
  • Not comfortable reading, writing, or speaking English or Spanish
  • Unwilling to participate in study procedures

Treatment and study plan

CBT-DAY (Cognitive Behavioral Therapy for Depression in Autistic Youth)

Behavioral

CBT-DAY (Cognitive Behavioral Therapy for Depression in Autistic Youth) is a 12-week, autism-adapted cognitive behavioral therapy designed for verbally fluent autistic youth aged 11-17 to reduce depressive symptoms.

The intervention targets key mechanisms-emotional reactivity, negative self-esteem, and autism self-knowledge-using developmentally tailored CBT strategies appropriate for autistic individuals.

Treatment-as-Usual (TAU)

Behavioral

Treatment-as-Usual (TAU) consists of standard clinical care delivered by clinicians with limited autism training in the same outpatient setting.

It typically involves supportive, talk-based psychotherapy without the structured, autism-adapted components of CBT-DAY.

Primary outcomes

  1. Change in depressive symptom severity

    Time frame: Baseline to week 24

    Change in depressive symptom severity as assessed by the Modified Depression Module of the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS). This is a semi-structured clinical interview evaluating DSM-5 depressive symptoms over the previous 2 weeks. Each symptom is rated on a 6-point scale (1 = not present to 6 = severe). Higher scores indicating greater symptom severity. The outcome will be evaluated as change in total depression severity scores over time and compared between CBT-DAY and TAU groups. The KSADS will be administered four times from baseline to 6 months.

Secondary outcomes

  1. Change in Anxiety Symptoms

    Time frame: Baseline to week 24

    Change in anxiety symptom severity as assessed by the Pediatric Anxiety Rating Scale adapted for Autism Spectrum Disorder (PARS-ASD). This is a semi-structured clinical interview assessing type and severity of anxiety symptoms. Each symptom is rated on a 6 point scale (0 = never to 5 = always). Higher scores indicate greater severity of anxiety symptoms. The outcome will be evaluated as change in anxiety scores over time and compared between CBT DAY and TAU groups. The PARS-ASD will be administered four times from baseline to 6 months.

  2. Change in Suicidal Ideation

    Time frame: Baseline to week 24

    Change in severity of suicidal ideation measured by the Suicidal Ideation Questionnaire-Junior (SIQ-Jr). This is a youth-report survey evaluating dfrequency of suicidal thoughts over the previous 2 weeks. Items are rated on a 7-point scale (0 = never to 6 = almost every day), with higher total scores indicating more severe suicidal ideation. The outcome will be evaluated as change in suicidal ideation scores over time and compared between CBT DAY and TAU groups. The SIQ-Jr will be administered four times from baseline to 6 months.

  3. Change in Life Satisfaction

    Time frame: Baseline to week 24

    Change in youth-reported life satisfaction measured using the PROMIS Pediatric Short Form - Life Satisfaction. This is a youth-report survey evaluating satisfaction with life over the past month. Items are rated on a 5-point scale, with higher scores indicating greater life satisfaction. The outcome will be evaluated as change in life satisfaction over time and compared between CBT DAY and TAU groups. The PROMIS will be administered four times from baseline to 6 months.

  4. Change in Emotional Reactivity

    Time frame: Baseline to week 24

    Change in emotional reactivity as assessed by the Emotion Dysregulation Inventory (EDI). This is a youth- and parent-report survey evaluating emotion dysregulation in youth. Each symptom is rated on a 5-point scale (0 = not at all to 4 = very severe). Higher scores indicate greater emotion dysregulation. The outcome will be evaluated as change in emotional dysregulation over time and compared between CBT DAY and TAU groups. The EDI will be administered four times from baseline to 6 months.

  5. Change in Self-Esteem

    Time frame: Baseline to week 24

    Change in self-esteem as assessed by the Rosenberg Self-Esteem Scale (RSES). This is a youth-report survey evaluating self-esteem. Each item is rated on a 4-point scale (1 = strongly disagree to 4 = strongly agree). Higher scores indicate higher self-esteem. The outcome will be evaluated as change in self-esteem scores over time and compared between CBT DAY and TAU groups. The RSES will be administered four times from baseline to 6 months.

  6. Change in Autism Self-Knowledge

    Time frame: Baseline to week 24

    Change in autism self-knowledge as assessed by the Autism Personal and Community Identity (APCI) scale. This is a youth-report survey evaluating autism self-knowledge. Each item is rated on a 6-point scale (1 = strong disagree to 6 = strongly agree). Higher scores indicate higher autism self-knowledge. The outcome will be evaluated as change in autism self-knowledge over time and compared between CBT DAY and TAU groups. The APCI will be administered four times from baseline to 6 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica Schwartzman, PhD

CONTACT

[email protected]

323-207-5910

Sponsors and collaborators

Lead sponsor

Children's Hospital Los Angeles

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Acronym: CBT-DAY

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.